FindTrial
Sign In

Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19)

Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032098
Enrollment
Unknown
Registered
2020-04-19
Start date
2020-01-20
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series :Western medicine plus Danggui Shaoyao Power

Sponsors

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. novel coronavirus pneumonia diagnostic criteria; 2. age unlimited, male and female unlimited.

Exclusion criteria

Exclusion criteria: 1. not qualified for novel coronavirus pneumonia diagnostic criteria; 2. Pregnant or lactating women who are allergic to the drug; 3. There are factors influencing the observation of curative effect; 4. Those who do not meet the inclusion criteria, fail to use the medicine according to the regulations, fail to determine the curative effect or incomplete data, which affect the judgment of curative effect or safety.

Design outcomes

Primary

MeasureTime frame
Blood routine;Blood biochemistry;C-reactive protein;chest CT;2019-ncov-RNA;TCM symptom;—

Countries

China

Contacts

Public ContactYang shenglan

Union Hospital

yangshenglan@126.com+86 13995641276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026